[go: up one dir, main page]

AR077866A1 - Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina - Google Patents

Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina

Info

Publication number
AR077866A1
AR077866A1 ARP100102968A ARP100102968A AR077866A1 AR 077866 A1 AR077866 A1 AR 077866A1 AR P100102968 A ARP100102968 A AR P100102968A AR P100102968 A ARP100102968 A AR P100102968A AR 077866 A1 AR077866 A1 AR 077866A1
Authority
AR
Argentina
Prior art keywords
antibody
bendamustine
combination therapy
afucosilated
afucosylated
Prior art date
Application number
ARP100102968A
Other languages
English (en)
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077866(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of AR077866A1 publication Critical patent/AR077866A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a la terapia de combinacion de un anticuerpo anti-CD20 afucosilado con bendamustina destinada al tratamiento del cáncer, especialmente a la terapia de combinacion de cánceres que expresan CD20 con un anticuerpo B-Ly1 humanizado afucosilado y bendamustina. Composicion que comprende dicho anticuerpo.
ARP100102968A 2009-08-14 2010-08-12 Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina AR077866A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14

Publications (1)

Publication Number Publication Date
AR077866A1 true AR077866A1 (es) 2011-09-28

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102968A AR077866A1 (es) 2009-08-14 2010-08-12 Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina

Country Status (35)

Country Link
US (4) US20110165151A1 (es)
EP (1) EP2464382B1 (es)
JP (3) JP5646626B2 (es)
KR (1) KR101425736B1 (es)
CN (2) CN102596245A (es)
AR (1) AR077866A1 (es)
AU (1) AU2010281866B2 (es)
BR (1) BR112012002855A2 (es)
CA (1) CA2769674C (es)
CL (1) CL2012000391A1 (es)
CR (1) CR20120036A (es)
CY (2) CY1119251T1 (es)
DK (1) DK2464382T3 (es)
ES (1) ES2630158T3 (es)
HK (1) HK1245145A1 (es)
HR (1) HRP20170972T1 (es)
HU (2) HUE033531T2 (es)
IL (1) IL217753A (es)
LT (2) LT2464382T (es)
LU (1) LUC00045I2 (es)
MA (1) MA33469B1 (es)
MX (2) MX355849B (es)
MY (1) MY163003A (es)
NO (1) NO2017054I1 (es)
NZ (1) NZ597666A (es)
PL (1) PL2464382T3 (es)
PT (1) PT2464382T (es)
RS (1) RS56146B1 (es)
SG (1) SG178324A1 (es)
SI (1) SI2464382T1 (es)
SM (1) SMT201700329T1 (es)
TW (1) TWI409079B (es)
UA (1) UA110096C2 (es)
WO (1) WO2011018224A1 (es)
ZA (1) ZA201200830B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ547589A (en) 2003-11-05 2009-05-31 Glycart Biotechnology Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
KR101559595B1 (ko) 2007-07-16 2015-10-12 제넨테크, 인크. 인간화 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
PL2474557T3 (pl) 2007-07-16 2015-02-27 Genentech Inc Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
IL295449A (en) 2008-01-31 2022-10-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
SG10201503991SA (en) 2010-05-31 2015-07-30 Ono Pharmaceutical Co Purinone derivative
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
SI2744515T1 (sl) * 2011-08-16 2022-05-31 Morphosys Ag Kombinirana terapija s protitelesom proti CD19 in dušikovim iperitom
HRP20220224T1 (hr) * 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
KR101636631B1 (ko) 2011-11-29 2016-07-05 오노 야꾸힝 고교 가부시키가이샤 퓨리논 유도체 염산염
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP6335284B2 (ja) 2013-06-07 2018-05-30 ノルディック ナノベクター エーエスエー 抗原発現を上方制御するための方法
ES2806506T3 (es) 2014-03-25 2021-02-17 Ono Pharmaceutical Co Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
ES2955554T3 (es) 2015-04-09 2023-12-04 Ono Pharmaceutical Co Proceso para producir un derivado de purinona
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
PT3796912T (pt) 2018-05-23 2023-05-17 Celgene Corp Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
ES2418360T3 (es) 1999-04-09 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4662473B2 (ja) 2002-10-17 2011-03-30 ゲンマブ エー／エス Ｃｄ２０に対するヒトモノクローナル抗体
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
NZ541503A (en) 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
KR20060012622A (ko) * 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
WO2005011735A1 (en) 2003-07-29 2005-02-10 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
JP2007504245A (ja) 2003-09-05 2007-03-01 ジェネンテック・インコーポレーテッド 変更したエフェクター機能を有する抗体
NZ547589A (en) * 2003-11-05 2009-05-31 Glycart Biotechnology Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CA2605697A1 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1931712B1 (en) 2005-08-26 2018-12-05 Roche Glycart AG Modified antigen binding molecules with altered cell signaling activity
CN103435695A (zh) * 2005-10-21 2013-12-11 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
WO2009083009A2 (en) * 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
WO2010083365A1 (en) * 2009-01-16 2010-07-22 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
EP2419470B1 (en) * 2009-04-15 2016-03-30 Invista Technologies S.à.r.l. Improving miscibility of otherwise immiscible compounds

Also Published As

Publication number Publication date
NO2017054I1 (no) 2017-10-26
TW201110980A (en) 2011-04-01
US20150093376A1 (en) 2015-04-02
CA2769674A1 (en) 2011-02-17
JP5963013B2 (ja) 2016-08-03
EP2464382B1 (en) 2017-05-03
MX355849B (es) 2018-05-02
US20120315268A1 (en) 2012-12-13
HUS000498I2 (hu) 2021-03-29
CY1119251T1 (el) 2018-02-14
CN107261138A (zh) 2017-10-20
CL2012000391A1 (es) 2012-08-24
ES2630158T3 (es) 2017-08-18
UA110096C2 (uk) 2015-11-25
PT2464382T (pt) 2017-06-30
HUE033531T2 (hu) 2021-12-28
SMT201700329T1 (it) 2017-09-07
CR20120036A (es) 2012-04-18
WO2011018224A1 (en) 2011-02-17
IL217753A (en) 2016-10-31
CN102596245A (zh) 2012-07-18
PL2464382T3 (pl) 2017-09-29
US20160166688A9 (en) 2016-06-16
AU2010281866B2 (en) 2016-05-12
KR101425736B1 (ko) 2014-08-01
CY2017034I1 (el) 2018-02-14
HUS1700041I1 (hu) 2017-11-28
TWI409079B (zh) 2013-09-21
JP5646626B2 (ja) 2014-12-24
JP2016222673A (ja) 2016-12-28
CA2769674C (en) 2018-01-23
SG178324A1 (en) 2012-03-29
MX2012001782A (es) 2012-04-19
NZ597666A (en) 2013-10-25
RS56146B1 (sr) 2017-11-30
JP2013501740A (ja) 2013-01-17
CY2017034I2 (el) 2018-02-14
LT2464382T (lt) 2017-07-25
KR20120054068A (ko) 2012-05-29
LTPA2017035I1 (lt) 2017-11-27
EP2464382A1 (en) 2012-06-20
HK1245145A1 (zh) 2018-08-24
MY163003A (en) 2017-07-31
LUC00045I1 (es) 2017-11-03
DK2464382T3 (en) 2017-07-17
HRP20170972T1 (hr) 2017-09-22
IL217753A0 (en) 2012-03-29
ZA201200830B (en) 2012-10-31
MA33469B1 (fr) 2012-07-03
US20140044705A1 (en) 2014-02-13
JP2015071611A (ja) 2015-04-16
BR112012002855A2 (pt) 2016-11-01
AU2010281866A1 (en) 2012-02-02
LUC00045I2 (es) 2018-02-26
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
RU2012109445A (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
TN2015000396A1 (en) Antibody drug conjugates
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
EA201171367A1 (ru) Винилиндазолильные соединения
EA201400178A1 (ru) Лечение рака молочной железы
CR20110553A (es) Terapia complementaria contra el cáncer
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
MX342590B (es) Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
MX2017014977A (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
CR11075A (es) Combinado de humano il-18 y anticuerpo anti cd20 para el tratamiento del cancer
CL2012000387A1 (es) Método para tratar a un paciente diagnosticado con cáncer de mama previamente tratado metastásico que comprende la combinación de una quimioterapia con la administración de un anticuerpo anti-vegf; y kit utilizado.

Legal Events

Date Code Title Description
FB Suspension of granting procedure